TMO · NYSE · STOCK
Thermo Fisher Scientific (TMO) Stock Analysis
$629.32
52W $435.27 – $643.99
62/100
$233.85B
33.8
0.85
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is TMO Bullish or Bearish?
Bullish.
Innellis AI committee rates Thermo Fisher Scientific (TMO) Buy with a composite score of 62/100
, based on 6 analysts with 83% agreement.
Last updated August 23, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.32 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.68 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is news sentiment is positive (+0.40 across 36 articles, 14d). The main limiting factor is p/e of 31.9 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- News sentiment is positive (+0.40 across 36 articles, 14d) — News
Bear Case
- P/E of 31.9 is moderate-to-rich — Value
- Price-to-book of 4.1x prices in significant intangible value — Value
- RSI at 80 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- Weekly RSI at 83 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 23, 2026
Overall Committee Score
62/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 26%
of 192 Healthcare peers
Value Analyst
bearish
35
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 31.9 is moderate-to-rich
Growth Analyst
bullish
68
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 80 is in overbought territory
Risk Analyst
bullish
70
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
70
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.40 across 36 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Investment Thesis Evolution
Committee score moved marginally from 61.7 to 61.7.
Comparing 2026-08-22 to 2026-08-23 (1 day apart).
Technical Analysis
RSI (14)
79.7
Overbought
MACD Histogram
1.426
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$554.60
Resistance
$643.71
Bollinger %B
1.02
Above Upper Band
Price vs Moving Averages
EMA 9
$606.33
Above
EMA 21
$587.29
Above
EMA 50
$554.48
Above
EMA 200
$523.57
Above
Fundamental Analysis
Valuation
27
Growth
73
Profitability
63
Financial Health
74
Cash Flow
70
Valuation
P/E Ratio
33.8×
P/B Ratio
4.43×
PEG Ratio
4.54
Dividend Yield
0.29%
52W High
$643.99
52W Low
$435.27
Quality & Growth
ROE
1261.5%
ROA
610.6%
Gross Margin
4037.2%
Operating Margin
1768.6%
Revenue Growth YoY
—
Debt / Equity
0.81
AI Fundamental Assessment
P/E ratio of 33.8 (rich relative to a 15-40x range); Price-to-book of 4.4x; PEG ratio of 4.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 12.6%; Return on assets of 6.1%; Net margin of 15.1%; Gross margin of 40.4%; Current ratio of 1.55 (healthy short-term liquidity); Debt-to-equity of 0.81; Free cash flow per share is positive (19.73); Most recent quarter beat estimates by 4.5%; 5 consecutive earnings beats; EPS growth accelerating (-17.2% -> +10.8% QoQ); Average YoY EPS growth of 12.5%; Analyst estimates falling over recent quarters
Get the Full TMO Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →